COST-UTILITY ANALYSIS OF FENOFIBRATE IN SLOWING PROGRESSION OF DIABETIC RETINOPATHY IN VIETNAM
Main Article Content
Abstract
Objective: To analyze the cost-utility of Fenofibrate in slowing the progression of diabetic retinopathy in Vietnam.
Subjects and methods: A model-based cost-utility analysis was performed from the payer perspective and the societal perspective, over a 10-year time horizon. A Markov model with 9 health states was used with a 1-year cycle length. The parameters of cost, clinical efficacy, and quality of life were collected from published literature.
Results: Fenofibrate was associated with both higher costs and greater clinical benefits. Compared to standard of care, Fenofibrate yielded an additional 0.3 quality-adjusted life years (QALYs). The incremental costs were VND 25.7 million from the societal perspective and VND 34.7 million from the payer perspective. The resulting ICERs per QALY gained were VND 84.5 million and VND 114.1 million, respectively, both falling below the one GDP per capita threshold for Vietnam in 2025. Sensitivity analyses robust the base-case results.
Conclusion: Fenofibrate is cost-effective in slowing the progression of diabetic retinopathy in Vietnam.
Article Details
Keywords
Diabetic retinopathy, Fenofibrate, cost effectiveness, cost utility analysis
References
[2] GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health, 2021, 9 (2): e144-e60. doi: 10.1016/s2214-109x(20)30489-7
[3] Nguyễn Thị Thủy Tiên, Trần Đình Tùng. Khảo sát bệnh lý võng mạc đái tháo đường trên bệnh nhân điều trị tại Bệnh viện Thống Nhất. Tạp chí Y học cộng đồng, 2024, 65 (CĐ10): 410-418. doi: 10.52163/yhc.v65iCD10.1657
[4] Pan Y, Li Y et al. Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Diabetes Obes Metab, 2025, 27 (10): 5464-77. doi: 10.1111/dom.16588
[5] Bộ Y tế. Hướng dẫn chẩn đoán, điều trị và quản lý bệnh võng mạc đái tháo đường (Ban hành kèm theo Quyết định số 2558/QĐ-BYT ngày 20/9/2022).
[6] Preiss D, Logue J et al. Effect of Fenofibrate on progression of diabetic retinopathy. NEJM Evid, 2024, 3 (8): EVIDoa2400179. doi: 10.1056/EVIDoa2400179
[7] Scotland G, Tsehaye M et al. Cost-effectiveness of Fenofibrate versus standard care for reducing the progression of diabetic retinopathy: an economic evaluation based on data from the LENS trial. Diabet Med, 2025, 42 (9): e70098. doi: 10.1111/dme.70098
[8] Pham Huy Tuan Kiet, Kieu Thi Tuyet Mai et al. Direct medical costs of diabetes and its complications in Vietnam: a national health insurance database study. Diabetes Res Clin Pract, 2020, 162: 108051. doi: 10.1016/j.diabres.2020.108051
[9] Srisubat A, Kittrongsiri K et al. Cost-utility analysis of deep learning and trained human graders for diabetic retinopathy screening in a nationwide program. Ophthalmol Ther, 2023, 12 (2): 1339-57. doi: 10.1007/s40123-023-00688-y
[10] Trần Thị Hoài Vi, Nguyễn Quốc Đạt, Nguyễn Hoàng Lan. Chất lượng cuộc sống và các yếu tố liên quan ở bệnh nhân võng mạc đái tháo đường tại thành phố Đà Nẵng. Tạp chí Y Dược Huế, 2025, 15 (5): 95-102. doi: 10.34071/jmp.2025.5.13